Clinical Trials Browser

Withdrawn × Colorectal Neoplasms × tislelizumab × Clear all

NCT05690035 2024-07-09

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT05582031 2023-06-07

REFIT-MSS

Phase 2 Withdrawn

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma